Share This Link

CA125 is a biomarker primarily associated with ovarian cancer, not cervical cancer. A decreased level would generally be considered favorable, or within normal limits (normal range typically < 35 U/mL), and would not indicate an increased risk for cervical cancer, which is typically screened via cytology and HPV testing.

While pelvic exams are part of routine gynecological care, their primary purpose is to assess the overall health of the reproductive organs. They can detect some abnormalities but are not as effective as Pap tests for specific early detection of cellular changes indicative of cervical cancer.

The BRCA1 gene is a tumor suppressor gene primarily linked to an increased risk of hereditary breast and ovarian cancers. While genetic predispositions can influence cancer risk, BRCA1 is not directly associated with the development of cervical cancer. Cervical cancer is predominantly caused by persistent human papillomavirus (HPV) infection.

The TNM staging system (T-tumor, N-node, M-metastasis) describes the anatomical extent of cancer. T4N2M2 indicates extensive disease, including distant metastases, meaning a cure is unlikely solely from local radiation. The statement implies a cure for the primary tumor, which contradicts the M2 staging.

The T4N2M2 staging indicates advanced, widespread disease, not a response to chemotherapy and radiation. If the tumor had responded and shrunk, the T and N classifications would likely be lower. Reducing analgesia would be inappropriate as pain management is crucial in advanced cancer.

This statement contradicts the T4 staging, which denotes a large primary tumor, not one that has shrunk. While some lymph nodes may remain involved (N2), the primary tumor's extensive nature (T4) and the presence of distant metastases (M2) define a more advanced and aggressive disease state.

Hyperkalemia, an elevated serum potassium level (normal range 3.5-5.0 mEq/L), is characterized by symptoms such as muscle weakness, fatigue, and cardiac arrhythmias, not typically tingling sensations in the extremities. This symptom constellation is distinct from neurological manifestations.

Hypocalcemia, a decreased serum calcium level (normal range 8.5-10.5 mg/dL), can cause neuromuscular irritability leading to symptoms like muscle spasms, tetany, and perioral numbness. While it can cause sensory disturbances, the generalized tingling in hands and feet is more indicative of peripheral nerve damage.

While diabetes can cause peripheral neuropathy due to chronic hyperglycemia damaging nerves, it is not a direct consequence of chemotherapy. The question specifically attributes the symptom to chemotherapy, making CIPN the most direct and likely cause in this context.
 

While breast cancer can metastasize to the skin, it is not the most common site. Skin metastases typically present as nodules or inflammatory changes and represent a less frequent pattern of dissemination compared to visceral or bony sites.

The lungs are a common site for breast cancer metastasis, often manifesting as pulmonary nodules or effusions. However, while significant, lung involvement is frequently accompanied by or preceded by metastasis to other prevalent sites.

The liver is another frequent site for breast cancer metastasis, leading to hepatic dysfunction and associated symptoms. While liver metastases are serious and common, they are still outranked by bone involvement as the most prevalent site.

Tumor lysis syndrome (TLS) involves the rapid breakdown of tumor cells, releasing their intracellular contents. This process leads to the release of intracellular potassium, resulting in hyperkalemia (increased potassium), not decreased potassium. Normal potassium levels are 3.5-5.0 mEq/L.

The release of large amounts of phosphate from lysed cells in TLS leads to hyperphosphatemia. This elevated phosphate then binds with calcium, causing calcium to precipitate out of solution, resulting in hypocalcemia (decreased calcium), not increased calcium. Normal calcium levels are 8.5-10.5 mg/dL.

As tumor cells lyse, they release intracellular phosphate into the bloodstream. This leads to a significant increase in serum phosphate levels, a condition known as hyperphosphatemia, which is characteristic of TLS. Therefore, decreased phosphate would be an incorrect finding. Normal phosphate levels are 2.5-4.5 mg/dL.

While anger is indeed a recognized stage of the Kubler-Ross grieving process, which can occur in response to illness and treatment, in this specific clinical scenario following radiation therapy, it is less likely to be the primary cause of sudden, uncharacteristic anger and demanding behavior. The physiological impact of radiation often takes precedence over psychological stages of grief in acute behavioral changes.

Notifying the healthcare provider for an anxiolytic might be considered if the anger were purely anxiety-driven. However, given the context of radiation therapy, the nurse must first consider physiological causes. Administering anxiolytics without investigating potential organic causes for behavioral changes could mask serious underlying complications, delaying appropriate medical intervention.

Assuming a "bad experience" is a premature conclusion. While patient experiences certainly influence behavior, a sudden, significant shift in personality and demeanor after a medical procedure, especially radiation, points more strongly towards a physiological or pharmacological side effect. The nurse's priority is to rule out medical complications before attributing behavior to psychosocial factors.

This response is dismissive of the client's immediate concerns and shifts responsibility back to the provider, undermining the nurse's role in patient education and support. It does not address the client's anxiety about the procedure itself and can make the client feel unheard and unimportant. The nurse should be capable of addressing common procedure-related questions.

Bone marrow biopsies are typically performed under local anesthesia, not general anesthesia, meaning the client will be awake during the procedure, although discomfort will be managed. Providing inaccurate information can lead to a breach of trust and increased anxiety if the client realizes the information was incorrect during the procedure.

While the client might be worried about the biopsy results, the direct question was about the pain of the procedure. This response deflects from the immediate concern about physical discomfort and instead interprets the client's underlying emotional state, which is not what was asked. The nurse should directly answer the client's explicit question first.

While an electrocardiogram (ECG) is crucial for monitoring cardiac function, Bleomycin is primarily known for its pulmonary toxicity, not direct cardiotoxicity requiring routine ECG monitoring in the absence of pre-existing cardiac conditions. Other chemotherapeutic agents like doxorubicin are more associated with cardiotoxicity, necessitating regular cardiac monitoring.

Measuring urinary output is a general nursing intervention for monitoring fluid balance and kidney function, which is important for many medications. However, Bleomycin is not primarily associated with significant nephrotoxicity that would necessitate specific, intensified urinary output monitoring beyond standard care compared to its prominent pulmonary effects.

Assessing hearing acuity is crucial for medications like cisplatin or aminoglycoside antibiotics, which are known to cause ototoxicity by damaging the hair cells in the cochlea. Bleomycin, however, does not have a primary adverse effect profile that includes ototoxicity, making this intervention less relevant specifically to Bleomycin administration.

Diarrhea is a common gastrointestinal side effect of many chemotherapeutic agents due to their cytotoxic effects on rapidly dividing cells of the intestinal lining. However, it is not a specific or dose-limiting adverse effect uniquely associated with vincristine, which is more renowned for its neurological toxicity.

Hair loss, or alopecia, is a widespread side effect of numerous chemotherapy drugs because they target rapidly dividing cells, including hair follicle cells. While vincristine can cause some hair thinning, it is not the most prominent or specific adverse effect for this medication compared to its well-documented neurotoxic profile.

Chest pain can be a symptom of various medical conditions, including cardiac issues or pulmonary complications from certain chemotherapeutic agents. However, chest pain is not a specific or common adverse effect directly attributable to vincristine's mechanism of action. Other agents like anthracyclines are known for cardiotoxicity.